Zoetis (ZTS) Osake Kurssi
Zoetis Kurssi
Liikevaihto on kasvanut 8,0 % vuodessa viimeisten 16 vuoden aikana 9,47 Mrd. USD:een. Osakekohtainen tulos on kasvanut 24,5 % vuodessa viimeisten 15 vuoden aikana. Zoetisn nettomarginaali on nyt 28,2 %, noussut 26,2 %:sta muutama vuosi sitten. Zoetisn osinkotuotto on tällä hetkellä noin 2,85 %. Jakosuhde on noin 33 % tuloksesta. Osinko on kasvanut 21,4 % vuodessa viimeisten 12 vuoden aikana. Analyytikoiden mediaanitavoitehinta on 85,00 USD, eli yli nykyhintaa 21,3 %. 24 analyytikosta 12 suosittaa ostoa — kokonaiskonsensus on Osta.
Zoetis osakekurssi
Zoetis liiketoimintamalli ja osakeanalyysi
Usein kysytyt kysymykset Zoetis -osakkeesta
Zoetis Inc. operates as a leading animal health company globally. The business model of Zoetis Inc. revolves around discovering, developing, manufacturing, and marketing a diverse range of animal health products and vaccines. With a focus on improving the health and well-being of animals, Zoetis aims to provide innovative solutions that enhance the health, productivity, and performance of livestock and companion animals. By offering a wide portfolio of products and services, Zoetis caters to the needs of veterinarians, livestock producers, and pet owners, thereby contributing to the overall welfare and sustainability of the animal health industry.
Zoetis Inc primarily operates in the animal health industry.
The main competitors of Zoetis Inc in the market are Merck & Co Inc, Elanco Animal Health Inc, and Boehringer Ingelheim GmbH.
Zoetis Inc is a leading global animal health company that specializes in the discovery, development, manufacture, and commercialization of a wide range of veterinary medicines and vaccines. Founded in 1952, Zoetis has a rich history of providing innovative solutions to improve the health and well-being of animals. With a strong commitment to research and development, the company has introduced numerous cutting-edge products and technologies that have revolutionized the field of animal health. Zoetis operates in more than 100 countries, serving veterinarians, livestock producers, and pet owners worldwide. This dedication to delivering high-quality, safe, and effective animal healthcare solutions has established Zoetis as a trusted name in the industry.
Zoetis Inc., a leading animal health company, has achieved several significant milestones in its history. Since its establishment in 2013 as a spin-off from Pfizer, Zoetis has continuously strived for innovation and growth. Some noteworthy milestones include its successful initial public offering (IPO) in 2013, becoming the largest animal health IPO in history. The company has also established itself as a global leader in animal health, expanding its presence in various markets worldwide. Additionally, Zoetis has consistently focused on research and development, introducing innovative products and solutions to address the health and well-being of animals. Through its dedication and expertise, Zoetis Inc. continues to make remarkable progress in the animal health industry.
Zoetis Inc., a leading animal health company, operates in various countries and regions worldwide. With a strong global presence, Zoetis primarily serves customers in North America, Europe, Africa, Asia, and Latin America. The company's extensive network allows it to deliver innovative animal health solutions and support to a diverse range of customers across these regions. Zoetis' commitment to expanding its reach and impact in the animal health industry is reflected in its presence and operations throughout these key locations.
Zoetis Inc represents a strong set of values and corporate philosophy. As a global animal health company, Zoetis Inc is committed to improving the health and well-being of animals by providing innovative products and services. With a focus on sustainability, they strive to make a positive impact on the world we live in. Zoetis Inc values integrity, accountability, collaboration, and customer focus. Their dedication to research and development ensures the delivery of high-quality solutions for animal health. By constantly evolving and embracing technological advancements, Zoetis Inc remains at the forefront of the industry, dedicated to improving the lives of animals, the people who care for them, and the communities they serve.
Analyytikot asettavat tällä hetkellä Zoetis-osakkeelle keskimääräisen tavoitehinnan 99,17 USD (mediaani: 85,00 USD), mikä merkitsee +42,3 % viimeisimpään hintaan verrattuna. Konsensus perustuu 24 analyytikkoarvioon.
24 analyytikkoa arvioi tällä hetkellä Zoetis-osaketta: 12 suosittaa ostoa, 12 pitoa ja 0 myyntiä. Vuodelle 2026 analyytikot odottavat Zoetis-yhtiöltä 9,29 Mrd. USD liikevaihtoa ja 6,33 USD osakekohtaista tulosta.
Nykyisellä valuuttakurssilla Zoetis-osake noteerataan hintaan 62,28 EUR (70,07 USD).
Zoetis-osake (ZTS) on listattuna 10 pörssissä, muun muassa: NYSE (ZTS), London (0M3Q.L), SIX (Zürich) (ZOE.SW), XETRA (ZOE.DE), Frankfurt (ZOE.F), München (ZOE.MU), Düsseldorf (ZOE.DU), Wien (ZOTS.VI).
Zoetis Inc is a leading company in the animal health industry that focuses on the development, manufacturing, and marketing of pharmaceuticals, vaccines, and diagnostic tests for animals. The company was founded in 1952 and is based in Parsippany, New Jersey. Zoetis operates in various segments including cattle production, swine production, poultry research and diagnostics, small animal practice, equine and livestock practice, and ectoparasiticides. The company offers several products that appeal to veterinarians and farmers. In the cattle range, Zoetis offers products such as EXCEDE, an injection that ensures sustained efficacy against pathogens in cattle, DRAXXIN, an injectable antibiotic for treating cattle with respiratory diseases and BRD, and LUTALYSE, a hormone that helps cattle breeders and livestock dealers during calving. In the swine production area, Zoetis offers products such as RESFLOR GOLD, a combination of antibiotics used for treating respiratory diseases, FOSTERA, a vaccine that provides immunity against Porcine Reproductive and Respiratory Syndrome (PRRS) and facilitates the approval of PRRS-infected swine, and DRAXXIN, a treatment for swine with respiratory disease. Zoetis is also involved in poultry research and diagnostics. Products such as FLOKILL, a medication for treating coccidiosis in chickens, Amprol, a medication for treating coccidiosis in chickens, Zeppelin, a test kit for identifying salmonella in poultry, and Bio-Chr, a feed additive that increases egg production in laying hens. In the small animal practice, Zoetis offers products such as Simparica, a medication for parasites like ticks and fleas in dogs, and Revolution and Proheart, both medications for parasites in dogs and cats. Zoetis also offers products for horses and livestock, including EQUIOXX, an anti-inflammatory for horses with arthritis and kissing spine, and CONVENIA, an antibiotic for horses, cows, and sheep. Zoetis is not only involved in the development and marketing of animal pharmaceuticals, but also in educating animal owners and farmers. They provide resources and training for animal health and care, and provide research data and information to animal owners. Zoetis' business model is to provide animal owners and farmers with innovative products and services that improve animal health and help keep animals healthy. The company specializes in developing and offering safe and effective products for animals used in food production to secure the food supply. Overall, Zoetis has a strong position in the animal pharmaceutical and diagnostic sector. The company aims to make a positive contribution to animals and animal owners through innovative products and close collaboration with animal owners.
odotettu liikevaihto Zoetis on 9,29 Mrd. USD. Tämä luku perustuu nykyisiin talousarvoihin ja heijastaa yhtiön liiketoimintasuoritusta.
odotettu voitto Zoetis on 2,78 Mrd. USD. Nettovoitto kuvastaa yhtiön kannattavuutta kaikkien kulujen vähentämisen jälkeen.
Zoetis:n hinta-voitto-suhde (P/E) on tällä hetkellä 11,07. P/E-suhde vertaa nykyistä osakekurssia osakekohtaiseen tulokseen ja auttaa sijoittajia arvioimaan Zoetis-osakkeen arvostusta.
Zoetis:n hinta-myynti-suhde (P/S) on tällä hetkellä 3,31. P/S-suhde vertaa markkina-arvoa vuosittaisiin tuloihin ja toimii Zoetis-osakkeen arvostuskennuslukuna.
Zoetis:n Eulpool-laatuscore on 8/10.
Zoetis:n ISIN on US98978V1035. ISIN (International Securities Identification Number) on maailmanlaajuisesti ainutlaatuinen arvopaperin tunnus.
Zoetis:n WKN on A1KBYX. WKN (Wertpapierkennnummer) on kuusinumeroinen saksalainen arvopaperin tunnus.
Zoetis:n ticker on ZTS. Tämä pörssinoteeraus käytetään Zoetis-osakkeiden kauppaan pörssissä.
Zoetis osake
Zoetis vertaisryhmä
Zoetis Ticker
Zoetis FIGI
Kaikki tunnusluvut ja syvällinen analyysi Zoetis:sta
Meidän osakeanalyysimme Zoetis-osakkeesta sisältää tärkeitä taloudellisia tunnuslukuja, kuten liikevaihdon, voiton, P/E-luvun, P/S-luvun, EBIT:n sekä tietoja osingosta. Lisäksi tarkastelemme asioita kuten osakkeet, markkina-arvo, velat, oma pääoma ja vastuut Zoetis:n yhteydessä. Jos etsit yksityiskohtaisempaa tietoa näistä aiheista, tarjoamme alisivuillamme kattavia analyysejä: